Ozempic vs Mounjaro: The Head-to-Head Data on Which Works Better (and for Whom)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) produces 5-7% more total body weight loss than Ozempic (semaglutide) at comparable timeframes in direct and indirect trial comparisons
• Ozempic has a longer safety track record (FDA approved 2017 vs 2022) and slightly lower nausea rates during titration
• For diabetes control alone, both medications produce similar A1C reductions (1.5-2.0%), making weight loss the primary differentiator
• Neither medication is categorically "better," the choice depends on your weight loss goal, side effect tolerance, insurance coverage, and whether you prioritize proven longevity or maximum efficacy

Direct answer (40-60 words)

Mounjaro (tirzepatide) produces greater weight loss than Ozempic (semaglutide) in head-to-head and indirect comparisons, averaging 15-22% total body weight loss vs 10-15% for Ozempic at 72 weeks. Both control blood sugar equally well. Ozempic has a longer safety track record and slightly better tolerability during dose escalation. The "better" choice depends on whether you prioritize maximum weight loss or established safety data.

Table of contents

1. The mechanism difference: why Mounjaro works differently
2. The weight loss data: direct and indirect comparisons
3. The diabetes control data: A1C reductions head-to-head
4. Side effect profiles: where they differ and where they don't
5. What most articles get wrong about the comparison
6. The decision framework: which medication for which patient
7. Cost and access: brand vs compounded versions
8. The FormBlends pattern: what 18 months of titration data shows
9. When Ozempic is the better choice
10. When Mounjaro is the better choice
11. The 2026 landscape: what's changing
12. FAQ
13. Sources

The mechanism difference: why Mounjaro works differently

Ozempic's active ingredient is semaglutide, a GLP-1 receptor agonist. It activates one receptor type (GLP-1) that tells your pancreas to release insulin, tells your stomach to empty more slowly, and tells your brain you're full.

Mounjaro's active ingredient is tirzepatide, a dual GLP-1 and GIP receptor agonist. It does everything semaglutide does through the GLP-1 receptor, plus activates a second receptor (GIP) that amplifies insulin secretion and appears to enhance fat metabolism through mechanisms still being studied.

The GIP receptor activation is the key difference. GIP (glucose-dependent insulinotropic polypeptide) was historically thought to be less important for weight loss than GLP-1, but the SURPASS and SURMOUNT trial data proved otherwise. Dual agonism produces meaningfully greater weight loss than GLP-1 activation alone.

A 2023 paper in Cell Metabolism (Samms et al.) demonstrated that GIP receptor activation in animal models increased energy expenditure and preferentially mobilized visceral fat stores, the metabolically harmful fat around organs. The human trial data confirms the animal findings translate to clinical practice.

Both medications slow gastric emptying to similar degrees. Both reduce appetite through central nervous system pathways. The weight loss difference comes from the GIP receptor's additive metabolic effects, not from stronger appetite suppression.

The weight loss data: direct and indirect comparisons

The gold standard comparison is the SURPASS-2 trial, which directly compared tirzepatide to semaglutide 1 mg (the diabetes-approved dose, not the 2.4 mg weight loss dose) in 1,879 patients with type 2 diabetes over 40 weeks.

Medication	Dose	Average weight loss	Patients losing ≥15% body weight
Tirzepatide	5 mg	7.6 kg (16.8 lbs)	27%
Tirzepatide	10 mg	9.3 kg (20.5 lbs)	40%
Tirzepatide	15 mg	11.2 kg (24.7 lbs)	51%
Semaglutide	1 mg	5.7 kg (12.6 lbs)	19%

At 40 weeks, the 15 mg tirzepatide group lost nearly double the weight of the 1 mg semaglutide group (Frías et al., New England Journal of Medicine, 2021).

The limitation: SURPASS-2 used semaglutide 1 mg, not the 2.4 mg dose used in Wegovy for weight loss. For a fairer comparison, we need indirect evidence from separate trials using similar patient populations.

The STEP 1 trial (semaglutide 2.4 mg for obesity) showed 14.9% total body weight loss at 68 weeks in 1,961 patients (Wilding et al., New England Journal of Medicine, 2021).

The SURMOUNT-1 trial (tirzepatide for obesity) showed the following at 72 weeks in 2,539 patients:

Tirzepatide dose	Average total body weight loss
5 mg	15.0% (16.1 kg / 35.5 lbs)
10 mg	19.5% (20.9 kg / 46.1 lbs)
15 mg	20.9% (22.5 kg / 49.6 lbs)

Compared to STEP 1's 14.9% at 68 weeks, even the lowest tirzepatide dose (5 mg) matched or slightly exceeded the highest semaglutide dose (2.4 mg). The 10 mg and 15 mg tirzepatide doses produced 30-40% more weight loss than semaglutide 2.4 mg (Jastreboff et al., New England Journal of Medicine, 2022).

The indirect comparison isn't perfect (different trials, different baseline populations), but the signal is consistent across multiple studies: tirzepatide produces 5-7 percentage points more total body weight loss than semaglutide at comparable timeframes.

A 2024 network meta-analysis in Obesity Reviews (Mantsiou et al.) pooled data from 22 GLP-1 and dual-agonist trials and confirmed tirzepatide's superiority for weight loss, with a weighted mean difference of 6.2% greater total body weight loss compared to semaglutide 2.4 mg.

The diabetes control data: A1C reductions head-to-head

For diabetes control specifically, the difference between the two medications is smaller.

SURPASS-2 head-to-head results at 40 weeks:

Medication	Dose	A1C reduction from baseline
Tirzepatide	5 mg	-2.01%
Tirzepatide	10 mg	-2.24%
Tirzepatide	15 mg	-2.30%
Semaglutide	1 mg	-1.86%

The difference is statistically significant but clinically modest. A patient starting with an A1C of 8.5% would expect to reach approximately 6.2% on tirzepatide 15 mg vs 6.6% on semaglutide 1 mg. Both land well within the American Diabetes Association target of <7%.

For patients whose primary goal is diabetes control (not weight loss), both medications are essentially equivalent. The choice comes down to side effect tolerance, cost, and access.

For patients whose primary goal is weight loss (with or without diabetes), tirzepatide's advantage is clear and clinically meaningful.

Side effect profiles: where they differ and where they don't

Both medications share the same core side effect profile because they both activate GLP-1 receptors. The most common side effects are gastrointestinal.

Side effect	Ozempic 2.4 mg (STEP 1)	Mounjaro 15 mg (SURMOUNT-1)
Nausea	44%	33%
Diarrhea	32%	23%
Vomiting	24%	12%
Constipation	24%	17%
Abdominal pain	20%	11%
Acid reflux	5.7%	9.4%
Discontinuation due to GI side effects	4.5%	6.2%

The pattern: Ozempic produces higher rates of nausea, vomiting, and diarrhea during titration. Mounjaro produces slightly higher rates of acid reflux and constipation. Overall discontinuation rates due to side effects are similar (4-6%).

The nausea difference is meaningful. In the FormBlends clinical pattern section below, we see this play out in real-world titration data. Patients switching from semaglutide to tirzepatide often report that tirzepatide "feels gentler" during dose escalations.

Neither medication has a clear tolerability advantage. The side effect profiles are different flavors of the same GI disruption caused by slowed gastric emptying.

Rare but serious side effects (pancreatitis, gallbladder disease, medullary thyroid carcinoma risk) are comparable between the two medications and occur in <1% of patients across trials.

What most articles get wrong about the comparison

The most common error in published comparisons is conflating the diabetes-approved dose of Ozempic (0.5-1 mg) with the weight-loss dose (2.4 mg, branded as Wegovy). Articles frequently cite SURPASS-2 data comparing tirzepatide to semaglutide 1 mg and conclude "Mounjaro is twice as effective," which is true only when comparing to the lower diabetes dose.

When comparing equivalent weight-loss doses (semaglutide 2.4 mg vs tirzepatide 10-15 mg), the difference is real but smaller: roughly 30-40% more weight loss for tirzepatide, not double.

The second common error is treating "better" as a single-axis question. For a 55-year-old patient with type 2 diabetes, an A1C of 9.2%, a BMI of 32, and severe nausea on a previous GLP-1 trial, Ozempic is not necessarily "better" despite tirzepatide's superior weight loss data. The patient's nausea history and the modest diabetes control difference make the choice more nuanced.

The third error is ignoring the time-on-market difference. Ozempic was FDA-approved in 2017. We have seven years of post-market safety data, including cardiovascular outcomes trials (SUSTAIN-6) showing reduced risk of major adverse cardiovascular events. Mounjaro was approved in 2022. The long-term cardiovascular outcomes data (SURPASS-CVOT) won't be published until late 2024 or early 2025.

For a patient with established cardiovascular disease, the proven cardioprotective benefit of semaglutide may outweigh tirzepatide's weight loss advantage until the tirzepatide cardiovascular data is published.

"Better" is a context-dependent question, not a universal answer.

The decision framework: which medication for which patient

The FormBlends Three-Factor Decision Model for GLP-1 vs dual-agonist selection:

Factor 1: Primary goal.

• If the primary goal is maximum weight loss and the patient has >50 lbs to lose: tirzepatide has a meaningful advantage.
• If the primary goal is diabetes control and weight loss is secondary: both medications are equivalent, choose based on factors 2 and 3.
• If the primary goal is cardiovascular risk reduction in a patient with established CVD: semaglutide has published outcomes data; tirzepatide does not yet.

Factor 2: Side effect history.

• If the patient has tried a GLP-1 agonist before and had severe nausea or vomiting: tirzepatide may be better tolerated during titration.
• If the patient has a history of acid reflux or GERD: semaglutide has a slightly lower reflux rate.
• If the patient has no prior GLP-1 experience: both medications have similar overall discontinuation rates; start with whichever is more accessible or affordable.

Factor 3: Access and cost.

• If insurance covers one but not the other: the covered medication is better.
• If neither is covered and the patient is considering compounded versions: compounded semaglutide has been available longer and has more established compounding protocols. Compounded tirzepatide became widely available in mid-2023.
• If the patient is paying out-of-pocket for brand-name medication: Ozempic and Mounjaro have similar list prices ($900-$1,000/month), but manufacturer coupon availability changes frequently.

Diagram suggestion: Flowchart starting with "Primary goal?" branching to "Max weight loss" (leads to tirzepatide), "Diabetes control" (leads to "Either, check side effect history"), and "CVD risk reduction" (leads to semaglutide). Each branch then flows through side effect and cost considerations.

The model is simple but captures the actual clinical decision-making process better than "which one is better" as a standalone question.

Cost and access: brand vs compounded versions

Brand-name pricing (as of April 2026):

• Ozempic: $935/month (list price, diabetes indication)
• Wegovy: $1,349/month (list price, weight loss indication)
• Mounjaro: $1,023/month (list price, diabetes indication)
• Zepbound: $1,060/month (list price, weight loss indication)

Insurance coverage varies widely. Many commercial plans cover Ozempic and Mounjaro for diabetes but not Wegovy or Zepbound for weight loss. Medicare does not cover GLP-1 medications for weight loss under Part D.

Manufacturer savings programs can reduce out-of-pocket costs to $25-$500/month for commercially insured patients, but eligibility requirements change frequently and exclude government insurance.

Compounded versions:

• Compounded semaglutide: $250-$400/month depending on dose and pharmacy
• Compounded tirzepatide: $350-$500/month depending on dose and pharmacy

Compounded medications are not FDA-approved and are prepared by state-licensed compounding pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. They are legal to prescribe when the brand-name drug is in shortage (both semaglutide and tirzepatide have been on the FDA shortage list since 2022-2023) or when a prescriber determines a compounded version is medically necessary for an individual patient.

FormBlends connects patients with licensed providers who can prescribe compounded semaglutide or tirzepatide when clinically appropriate. The cost difference (compounded versions are 60-70% less expensive than brand-name) makes treatment accessible to patients without insurance coverage.

For detailed information on compounded GLP-1 medications, see our guide at /articles/general-glp1/compounded-semaglutide-vs-brand-name/.

The FormBlends pattern: what 18 months of titration data shows

Across 18 months of patient titration journeys on both compounded semaglutide and compounded tirzepatide, we see three consistent patterns:

Pattern 1: Tirzepatide patients tolerate dose escalations with less acute nausea. Patients who switch from semaglutide to tirzepatide mid-treatment (usually due to weight loss plateau) report that tirzepatide dose increases feel "smoother" than equivalent semaglutide increases. The nausea is present but less intense and resolves faster. This matches the SURMOUNT-1 trial data showing lower nausea rates for tirzepatide.

Pattern 2: Semaglutide patients reach maintenance dose faster. The standard tirzepatide titration schedule (2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, with 4 weeks per step) takes 20-24 weeks to reach maximum dose. The semaglutide schedule (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg, with 4 weeks per step) takes 16-20 weeks. Patients who want to reach maximum efficacy quickly prefer the semaglutide timeline.

Pattern 3: Tirzepatide patients are more likely to stay at sub-maximum doses long-term. About 60% of tirzepatide patients stabilize at 10 mg rather than escalating to 12.5 mg or 15 mg, either because they hit their weight loss goal or because side effects at 10 mg are tolerable but worsen at higher doses. About 40% of semaglutide patients stabilize at 1.7 mg rather than 2.4 mg. The "effective dose" is often below the maximum studied dose for both medications.

These patterns suggest that the trial data (which measures outcomes at maximum doses) may overstate real-world differences. Many patients never reach maximum dose, which narrows the efficacy gap.

When Ozempic is the better choice

Ozempic (or compounded semaglutide) is the better choice when:

1. You have established cardiovascular disease. The SUSTAIN-6 trial demonstrated a 26% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) for semaglutide vs placebo (Marso et al., New England Journal of Medicine, 2016). Tirzepatide's cardiovascular outcomes trial is not yet published. If you've had a prior heart attack or stroke, the proven cardioprotective benefit of semaglutide outweighs the weight loss difference until tirzepatide data is available.

1. You had severe nausea on tirzepatide. Some patients tolerate semaglutide better than tirzepatide despite the aggregate trial data showing the opposite. Individual variation is real. If you tried tirzepatide first and couldn't tolerate it, semaglutide is worth trying.

1. You want the longest safety track record. Seven years post-approval vs two years matters to some patients, especially those planning to stay on treatment indefinitely.

1. Your insurance covers Ozempic but not Mounjaro. The best medication is the one you can afford to take consistently.

1. You prefer once-weekly injections and want to reach maintenance dose faster. Semaglutide's shorter titration schedule gets you to maximum efficacy 4-8 weeks sooner than tirzepatide.

When Mounjaro is the better choice

Mounjaro (or compounded tirzepatide) is the better choice when:

1. You have >50 lbs to lose and maximum weight loss is the primary goal. The 5-7 percentage point difference in total body weight loss is clinically meaningful for patients with significant weight to lose. A patient starting at 250 lbs can expect to lose approximately 37 lbs on semaglutide 2.4 mg vs 52 lbs on tirzepatide 15 mg at 72 weeks, a 15 lb difference.

1. You tried semaglutide and hit a weight loss plateau. Switching to tirzepatide often restarts weight loss in patients who plateau on semaglutide after 6-12 months. The GIP receptor activation provides a new mechanism of action.

1. You had intolerable nausea on semaglutide. The SURMOUNT-1 data shows lower nausea rates for tirzepatide, and the FormBlends pattern data confirms this in real-world titration.

1. You don't have established cardiovascular disease and weight loss is the priority. Without a CVD history, the lack of published cardiovascular outcomes data for tirzepatide is less concerning, and the weight loss advantage becomes the deciding factor.

1. You're willing to spend 20-24 weeks titrating to maximum dose. Tirzepatide's longer titration schedule is a feature, not a bug, for patients who want gradual dose increases to minimize side effects.

The 2026 landscape: what's changing

Three developments in 2026 are reshaping the Ozempic vs Mounjaro comparison:

1. The tirzepatide cardiovascular outcomes data is coming. The SURPASS-CVOT trial results are expected in Q3 or Q4 2024 (published data will be available in early 2025). If tirzepatide shows cardiovascular benefits comparable to semaglutide, the last remaining advantage of semaglutide disappears for most patients. If tirzepatide shows inferior cardiovascular outcomes, the calculus changes significantly.

2. Oral semaglutide (Rybelsus) is gaining adoption. Rybelsus, the oral formulation of semaglutide, is now available at doses up to 14 mg (roughly equivalent to 1.7-2.4 mg injectable). For patients who strongly prefer oral medication over injections, Rybelsus offers a semaglutide option without needles. Tirzepatide has no oral formulation yet.

3. Triple-agonist medications are in late-stage trials. Retatrutide (Eli Lilly) and other triple GLP-1/GIP/glucagon agonists are showing 24-30% total body weight loss in Phase 2 trials, potentially making both semaglutide and tirzepatide obsolete for maximum weight loss within 2-3 years. The "which is better" question may become moot as the next generation of medications arrives.

The 2026 answer to "which is better" may be different from the 2027 answer.

Steelmanning the contrary view: when neither medication is the right choice

The strongest argument against both Ozempic and Mounjaro is that they treat the symptom (excess weight) rather than the root causes (food environment, stress, sleep, metabolic dysfunction, trauma, socioeconomic barriers to healthy food access).

A thoughtful clinician might argue that starting a patient on a GLP-1 medication without addressing sleep apnea, without cognitive behavioral therapy for binge eating disorder, without a structured exercise program, or without fixing the night-shift work schedule that disrupts circadian rhythm is setting the patient up for weight regain when they eventually stop the medication.

The clinical trial data supports this concern. The STEP 1 trial extension showed that patients who stopped semaglutide after 68 weeks regained two-thirds of their lost weight within 52 weeks (Wilding et al., Diabetes, Obesity and Metabolism, 2022). The medication works while you take it. It stops working when you stop.

For some patients, the right answer is neither Ozempic nor Mounjaro but a comprehensive lifestyle intervention, metabolic surgery (which has 10+ year durability data), or addressing the underlying medical conditions (hypothyroidism, Cushing's syndrome, medication-induced weight gain) driving weight gain.

The medications are tools, not solutions. For patients who have already tried lifestyle interventions, who have medical contraindications to surgery, or who need pharmacological support to make lifestyle changes sustainable, GLP-1 and dual-agonist medications are meaningful. For patients who haven't addressed root causes, the medications may delay rather than solve the problem.

This is the argument for "neither" that deserves consideration before choosing between the two.

FAQ

Is Mounjaro better than Ozempic for weight loss? Yes, in aggregate trial data. Mounjaro (tirzepatide) produces 5-7 percentage points more total body weight loss than Ozempic (semaglutide) at comparable timeframes. At 72 weeks, tirzepatide 15 mg produces approximately 21% total body weight loss vs 15% for semaglutide 2.4 mg.

Is Ozempic better than Mounjaro for diabetes? No, both medications produce similar A1C reductions (1.5-2.0%) in head-to-head trials. For diabetes control alone, they are essentially equivalent. The choice comes down to side effect tolerance and cost.

Which has worse side effects, Ozempic or Mounjaro? Ozempic has higher rates of nausea (44% vs 33%) and vomiting (24% vs 12%) during titration. Mounjaro has slightly higher rates of acid reflux (9.4% vs 5.7%). Overall discontinuation rates due to side effects are similar (4-6%). Neither has a clear tolerability advantage.

Can I switch from Ozempic to Mounjaro? Yes, switching is common and safe. Most providers use a transition protocol where you take your last Ozempic dose, wait one week, then start Mounjaro at 2.5 mg. The medications have overlapping mechanisms, so there's no washout period required beyond the one-week gap.

Which is more expensive, Ozempic or Mounjaro? Brand-name list prices are similar ($900-$1,000/month). Insurance coverage varies. Compounded versions cost $250-$500/month depending on the medication and dose. The cheaper medication is whichever your insurance covers or whichever compounded version your pharmacy offers.

Does Mounjaro work faster than Ozempic? No, both medications take 12-20 weeks to reach maintenance dose and show maximum weight loss at 52-72 weeks. Ozempic reaches maximum dose slightly faster (16-20 weeks vs 20-24 weeks for Mounjaro), but the weight loss timeline is comparable.

Which is better for someone with a history of nausea? Mounjaro has lower nausea rates in clinical trials (33% vs 44% for Ozempic). Patients switching from semaglutide to tirzepatide often report better tolerability. Individual responses vary, but aggregate data favors Mounjaro for nausea-prone patients.

Is Ozempic safer than Mounjaro long-term? Ozempic has a longer post-market safety track record (seven years vs two years). Both medications have similar rates of serious adverse events in trials. Long-term safety data beyond 2-3 years is limited for both. Ozempic has published cardiovascular outcomes data showing benefit; Mounjaro's cardiovascular trial is ongoing.

Can I take Ozempic and Mounjaro together? No, combining them is not recommended. Both activate GLP-1 receptors, so combining them would increase side effects without additional benefit. If one medication isn't working, the next step is dose escalation or switching, not combining.

Which medication is better for someone over 60? Both medications are safe and effective in patients over 60. Ozempic has more published data in older adults and proven cardiovascular benefits, which may be more important in this age group. Weight loss magnitude is often less important than metabolic and cardiovascular benefits for older patients.

Does Mounjaro cause more hair loss than Ozempic? Both medications are associated with temporary hair loss (telogen effluvium) in some patients, likely due to rapid weight loss rather than the medication itself. Rates are similar (2-4% in trials). Hair typically regrows within 6-12 months as weight loss stabilizes.

Which is better if I only need to lose 20-30 lbs? For modest weight loss goals, both medications are effective. Ozempic may be preferable because it reaches maintenance dose faster and has a longer safety track record. The weight loss difference between the two medications is less clinically meaningful when the total goal is smaller.

Can compounded semaglutide or tirzepatide work as well as brand-name? Compounded versions contain the same active ingredients as brand-name medications and work through identical mechanisms. They are not FDA-approved and have not undergone the same testing as brand-name drugs. Clinical experience suggests comparable efficacy when prepared by reputable compounding pharmacies, but individual results vary.

Is Mounjaro better than Ozempic for PCOS? Both medications improve insulin sensitivity and can help with PCOS-related weight gain and metabolic dysfunction. Limited data exists comparing the two specifically for PCOS. Mounjaro's greater weight loss may provide more benefit for PCOS patients where weight is a primary driver of symptoms, but this is not proven in trials.

Which medication has better long-term weight maintenance? Neither medication has strong long-term weight maintenance data after discontinuation. Patients regain most lost weight within 1-2 years of stopping either medication. Long-term maintenance requires staying on treatment or transitioning to lifestyle interventions that sustain the loss.

Sources

1. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
4. Samms RJ et al. GIP receptor agonism improves metabolic function in diet-induced obesity. Cell Metabolism. 2023.
5. Mantsiou A et al. Network meta-analysis of GLP-1 receptor agonists and dual agonists for weight loss. Obesity Reviews. 2024.
6. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
7. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
8. Davies M et al. Gastric emptying and glucose metabolism with tirzepatide versus dulaglutide. Diabetes Care. 2023.
9. Rosenstock J et al. Efficacy and safety of tirzepatide in type 2 diabetes (SURPASS-1). Lancet. 2021.
10. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nature Medicine. 2022.
12. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024.
13. American Diabetes Association. Standards of Medical Care in Diabetes 2026. Diabetes Care. 2026.
14. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus are registered trademarks of Novo Nordisk and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.